ABT · News · 20261113N
Segment Demand Trends
ABBOTT LABORATORIES · 2026-11-13 · Importance 31 · Surprise 40
Abbott’s Established Pharmaceuticals segment reportedly delivered broad-based growth across geographies and therapeutic areas. Medical Devices benefited from double-digit growth in Electrophysiology and Rhythm Management. Diagnostics demand was supported by Core Laboratory testing and continued momentum in Cancer Diagnostics.
Key facts
- Abbott's Established Pharmaceuticals (EPD) delivered broad-based growth across geographies and therapeutic areas in Q3 2026. source
- Abbott's Medical Devices segment benefited from double-digit growth in Electrophysiology and Rhythm Management in Q3 2026. source
- Abbott's Diagnostics segment gained from strong Core Laboratory testing demand and continued momentum in Cancer Diagnostics in Q3 2026. source